8-K: NextCure Forges Global Partnership with Simcere Zaiming for Novel Cancer Therapies and Secures Strategic Investment

NextCure, Inc. has entered into a strategic licensing agreement with Simcere Zaiming, gaining exclusive global rights to a clinical-stage antibody-drug conjugate (ADC) targeting CDH6, SIM0505, and access to proprietary ADC technology, alongside a $2.0 million private placement.

Summary

• NextCure, Inc. (NextCure) has signed a License Agreement with Hainan Simcere Zaiming Pharmaceutical Co., Ltd. (Zaiming) for a strategic partnership.
• NextCure obtained an exclusive, worldwide license (excluding mainland China, Hong Kong, Macau, and Taiwan) to develop, manufacture, and commercialize Zaiming's clinical-stage antibody drug conjugate (ADC) candidate, SIM0505, and related compounds.
• NextCure also received a non-exclusive, worldwide license (excluding Zaiming Territory) to use Zaiming's ADC platform technology for developing ADCs based on NextCure's proprietary antibodies for an additional novel target.
• NextCure will pay Zaiming an upfront cash payment of $12 million, with an additional $5 million due upon a qualifying financing event or by December 31, 2025.
• Further payments include $1 million in common stock (or cash) upon initiation of the first Phase 2 clinical trial for SIM0505, up to $166.5 million per Zaiming Product in development and regulatory milestones, and up to $25.5 million per NextCure Product in development and regulatory milestones.
• Commercial sales-based milestone payments could reach up to $535 million, along with tiered royalties on annual net sales ranging from mid-single digit to low double digit percentages for Zaiming Products, and low to mid-single digit percentages for NextCure Products.
• NextCure will be responsible for clinical development and commercialization of SIM0505 in the United States and other countries outside the Zaiming Territory, while Zaiming retains exclusive rights and will continue development in the Zaiming Territory.
• Concurrently, NextCure entered into a Subscription Agreement with Simcere Zaiming, Inc., an affiliate of Zaiming, for a private placement of 4,063,633 shares of common stock at approximately $0.492 per share, totaling $2.0 million.
• NextCure believes its existing cash, cash equivalents, and marketable securities will be sufficient to fund planned operations into mid-2026, though this estimate is subject to assumptions that may prove incorrect.
• SIM0505 is currently in Phase 1 clinical testing in China, with NextCure expecting to begin U.S. clinical testing in the third quarter of 2025, and initial Phase 1 clinical data anticipated in the first half of 2026.
• The company also highlighted its ongoing Phase 1 dose escalation study for LNCB74 (B7-H4 ADC), initiated in January 2025, with POC expected in the first half of 2026.

Sentiment

Score: 8

Explanation: The document outlines a significant strategic partnership that expands NextCure's pipeline with a clinical-stage asset and proprietary technology, backed by a strategic investment. This diversification and external validation are strong positives for a clinical-stage biopharmaceutical company, despite the associated future milestone obligations and minor dilution.

Positives

• NextCure gains exclusive global rights (ex-Greater China) to SIM0505, a clinical-stage ADC targeting CDH6, expanding its pipeline with a promising asset.
• The partnership provides NextCure access to Simcere Zaiming's proprietary ADC platform technology, including a unique linker and TOPOi payload, for developing new ADCs based on NextCure's own antibodies.
• SIM0505 has demonstrated robust anti-tumor activity in preclinical studies across multiple solid tumor models and a promising safety profile in toxicology models.
• Initial Phase 1 clinical data for SIM0505 in China shows a partial response (PR) at the lowest dose in a patient with serous endometrial carcinoma, with a 43% reduction in target lesions and no DLTs or Grade 3 TEAEs observed at initial dose levels.
• The U.S. FDA has cleared an Investigational New Drug (IND) application for SIM0505, allowing NextCure to initiate a U.S. Phase 1 clinical trial in Q3 2025.
• The collaboration with Simcere Zaiming, a leader in antibody-drug conjugates, leverages external expertise and resources for accelerated drug development.
• The private placement of $2.0 million provides additional capital, albeit a small amount, from a strategic partner, reinforcing the partnership.

Negatives

• NextCure is obligated to pay significant potential development, regulatory, and commercial sales-based milestone payments totaling up to $745 million, plus tiered royalties, which could be substantial if products are successful.
• The private placement, while providing capital, involves the issuance of 4,063,633 shares, leading to some dilution for existing shareholders.
• The company's estimate of cash runway into mid-2026 is based on assumptions that may prove incorrect, indicating potential future financing needs.

Risks

• NextCure's limited operating history and lack of approved commercial products pose inherent business risks.
• The company has a history of significant losses and will require additional financing, which may not be obtainable on acceptable terms or at all, potentially exhausting capital resources sooner than expected.
• Clinical development of SIM0505 and LNCB74 is subject to risks, and positive results in preclinical studies may not be predictive of clinical trial outcomes.
• There are risks associated with obtaining marketing approval and successful commercialization of any therapeutic candidates.
• NextCure's ability to maintain its listing on the Nasdaq Global Select Market is crucial for its public trading status.
• The company's dependence on key personnel is a risk factor for its operations and strategic execution.

Future Outlook

NextCure expects to initiate a U.S. Phase 1 clinical trial for SIM0505 in the third quarter of 2025, with initial Phase 1 clinical data from both China and U.S. studies anticipated in the first half of 2026. The company also projects Proof of Concept (POC) data for its LNCB74 program in the first half of 2026. NextCure estimates its current cash, cash equivalents, and marketable securities will fund operations into mid-2026, though acknowledges this is an estimate based on assumptions that may prove incorrect.

Management Comments

• Michael Richman, NextCure's president and CEO, stated: "We believe SIM0505 has the potential to be an important new therapy for cancer patients. Partnering with Simcere Zaiming, a leader in antibody-drug conjugates, provides us with an opportunity to advance a class-leading ADC directed to CDH6. Their proprietary payload is a potent cytotoxin with a potentially improved safety and efficacy profile compared to other topoisomerase inhibitors. We look forward to initiating clinical development of SIM0505 in the United States."
• Renhong Tang, PhD, CEO of Simcere Zaiming, commented: "We are very pleased to collaborate with NextCure on the global development of SIM0505. SIM0505 is a significantly differentiated CDH6 targeting ADC candidate independently developed by Simcere Zaiming. Our alliance reflects NextCure's recognition of our proprietary ADC platform, and together, we aim to accelerate drug development to benefit more cancer patients worldwide."

Industry Context

This strategic partnership positions NextCure more strongly in the competitive and rapidly evolving antibody-drug conjugate (ADC) market, a key area of innovation in oncology. By licensing a clinical-stage asset (SIM0505) and gaining access to a proprietary ADC platform from Simcere Zaiming, a China-based biopharmaceutical company, NextCure expands its pipeline and leverages external R&D capabilities. This move aligns with a broader industry trend of collaborations and licensing deals to accelerate drug development and share risks, particularly for complex modalities like ADCs. The focus on CDH6 and B7-H4 targets indicates a strategy to address unmet needs in solid tumors, including ovarian, lung, renal, breast, and endometrial cancers, which are areas of high interest for new therapeutic options.

Comparison to Industry Standards

• **SIM0505 (CDH6 ADC)**: Compared to competitors like DS-6000 (Daiichi Sankyo/AstraZeneca, in Phase 3), CUSP06, HS-20124, and QLS-5133. SIM0505 differentiates itself with a unique binding epitope, increased affinity, and Simcere Zaiming's proprietary CPT116 TOPOi payload designed for high systemic clearance and a potentially improved safety profile compared to other topoisomerase inhibitors. While DS-6000 has reported an ORR of 46% in ovarian cancer and a DCR of 98% in its Phase 1, SIM0505's initial Phase 1 data (China) shows a partial response at the lowest dose with no DLTs or Grade 3 TEAEs, suggesting a promising early safety and efficacy profile that warrants further investigation against these established competitors.
• **LNCB74 (B7-H4 ADC)**: Compared to XMT-1660 (Mersana Therapeutics), HS-20089, AZD8205 (AstraZeneca), and DB-1312/BG-C9074. LNCB74 utilizes a differentiated glucuronidase cleavable linker and MMAE payload, designed for improved safety and increased efficacy through site-specific attachment and efficient, tumor-specific toxin release. This contrasts with competitors using protease cleavable linkers or different payloads. LNCB74's preclinical data showed potent anti-tumor activity in various models, including 100% complete responses in a TNBC PDX model at 6 mg/kg, which is a strong indicator of efficacy compared to general industry benchmarks for preclinical ADCs. The document highlights LNCB74's potential for improved safety and efficacy over comparator B7-H4-MMAE ADCs.

Related Party Transactions

• NextCure, Inc. entered into a Subscription Agreement with Simcere Zaiming, Inc., a Delaware corporation and an affiliate of Hainan Simcere Zaiming Pharmaceutical Co., Ltd., for a private placement of 4,063,633 shares of common stock for $2.0 million.

Stakeholder Impact

• **Shareholders**: Potential for increased value through pipeline expansion and strategic validation, but also dilution from the private placement and future milestone payment obligations. The cash runway extension provides some stability.
• **Employees**: Potential for increased R&D activities and job security due to pipeline expansion and extended funding runway.
• **Customers (Future Patients)**: Potential for new, differentiated cancer therapies (SIM0505 and NextCure Products) to address unmet medical needs in solid tumors.
• **Creditors**: Extended cash runway into mid-2026 may reduce immediate concerns about liquidity, but future capital raises remain a possibility.

Next Steps

• NextCure will initiate a U.S. Phase 1 clinical trial for SIM0505 in the third quarter of 2025.
• Initial Phase 1 clinical data for SIM0505 (from both China and U.S. studies) is expected in the first half of 2026.
• Proof of Concept (POC) data for LNCB74 is expected in the first half of 2026.
• NextCure is obligated to prepare and file a registration statement with the SEC to register for resale the shares issued in the private placement, and use reasonable best efforts to cause it to be declared effective.
• If required by Nasdaq rules, NextCure will seek stockholder approval for the issuance of shares and will submit the proposal at least semi-annually until approval is obtained.

Key Dates

Recommendation

Keywords

NextCure, Simcere Zaiming, License Agreement, Antibody-Drug Conjugate, ADC, SIM0505, CDH6, Oncology, Cancer Therapy, Clinical Trial, Phase 1, Biopharmaceutical, Private Placement, Equity Financing, LNCB74, B7-H4, Solid Tumors, Drug Development, Strategic Partnership, SEC Filing, Form 8-K